| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Journal of Clinical Endocrinology & Metabolism, Vol 81, 3222-3230, Copyright © 1996 by Endocrine Society
ARTICLES |
Q Dou, Y Zhao, RW Tarnuzzer, H Rong, RS Williams, GS Schultz and N Chegini
Department of Obstetrics and Gynecology, University of Florida College of Medicine, Gainesville 32610, USA.
The expression and cellular distribution of transforming growth factor- 1 (TGF beta 1) through TGF beta 3 and TGF beta type I-III receptor messenger ribonucleic acid (mRNA) and protein were analyzed in leiomyomata from patients receiving GnRH agonist (GnRHa; leuprolide acetate) compared to those in untreated controls. Standard reverse transcription-PCR revealed that the unaffected myometrium and leiomyomata from leuprolide-treated and untreated patients express TGF beta 1-3 and TGF beta type I-III receptor mRNA. The myometrial and leiomyomata smooth muscle cells were the primary site of TGF beta 1-3 and TGF beta type I and II receptor mRNA and protein expression, as determined by in situ hybridization and immunohistochemical localization. These observations indicate that leiomyomata express a higher of level of TGF beta and TGF beta receptor mRNA and protein than unaffected myometrium during the secretory phase of the menstrual cycle, and women who received leuprolide acetate therapy had a substantially lower level of expression than untreated controls. Furthermore, competition-based quantitative reverse transcription-PCR using synthetic internal standards revealed that leiomyomata express a significantly higher number (copies per cell) of TGF beta type II receptor mRNA, followed by TGF beta 1, TGF beta type I receptor, TGF beta 2, and TGF beta 3 (P < 0.05). However, there was a significant decrease in the levels (copies per cell) of TGF beta 1, TGF beta 3, and TGF beta type I and type II receptor mRNA expression in leiomyomata from leuprolide-treated compared to untreated patients (P < 0.05). The data provide further evidence that leiomyomata express mRNA and protein for all components of the TGF beta system, and GnRHa therapy results in down-regulation of their expression. More specifically, these data suggest that TGF beta 1 and TGF beta 3 may play a more important role in leiomyomata growth than TGF beta 2, which leads us to propose that lowering TGF beta and receptor expression may have a direct effect on leiomyomata regression.
This article has been cited by other articles:
![]() |
P. S. Tanwar, H.-J. Lee, L. Zhang, L. R. Zukerberg, M. M. Taketo, B. R. Rueda, and J. M. Teixeira Constitutive Activation of Beta-Catenin in Uterine Stroma and Smooth Muscle Leads to the Development of Mesenchymal Tumors in Mice Biol Reprod, September 1, 2009; 81(3): 545 - 552. [Abstract] [Full Text] [PDF] |
||||
![]() |
K.L. Greathouse, J.D. Cook, K. Lin, B.J. Davis, T.D. Berry, T.G. Bredfeldt, and C.L. Walker Identification of Uterine Leiomyoma Genes Developmentally Reprogrammed by Neonatal Exposure to Diethylstilbestrol Reproductive Sciences, October 1, 2008; 15(8): 765 - 778. [Abstract] [PDF] |
||||
![]() |
N. Ohara, A. Morikawa, Wei Chen, Jiayin Wang, D. A. DeManno, K. Chwalisz, and T. Maruo Comparative Effects of SPRM Asoprisnil (J867) on Proliferation, Apoptosis, and the Expression of Growth Factors in Cultured Uterine Leiomyoma Cells and Normal Myometrial Cells Reproductive Sciences, December 1, 2007; 14(8_suppl): 20 - 27. [Abstract] [PDF] |
||||
![]() |
Y. Zhao, Y. Wen, M. L. Polan, J. Qiao, and B. H. Chen Increased expression of latent TGF-{beta} binding protein-1 and fibrillin-1 in human uterine leiomyomata Mol. Hum. Reprod., May 1, 2007; 13(5): 343 - 349. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Wang, N. Ohara, Z. Wang, W. Chen, A. Morikawa, H. Sasaki, D. A. DeManno, K. Chwalisz, and T. Maruo A novel selective progesterone receptor modulator asoprisnil (J867) down-regulates the expression of EGF, IGF-I, TGFbeta3 and their receptors in cultured uterine leiomyoma cells Hum. Reprod., July 1, 2006; 21(7): 1869 - 1877. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Luo, E. Levens, R. S. Williams, and N. Chegini The expression of Abl interactor 2 in leiomyoma and myometrium and regulation by GnRH analogue and transforming growth factor-beta Hum. Reprod., June 1, 2006; 21(6): 1380 - 1386. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. De Falco, S. Staibano, F. P. D'Armiento, M. Mascolo, G. Salvatore, A. Busiello, I. F. Carbone, F. Pollio, and A. Di Lieto Preoperative Treatment of Uterine Leiomyomas: Clinical Findings and Expression of Transforming Growth Factor-{beta}3 and Connective Tissue Growth Factor Reproductive Sciences, May 1, 2006; 13(4): 297 - 303. [Abstract] [PDF] |
||||
![]() |
X. Luo, L. Ding, and N. Chegini CCNs, fibulin-1C and S100A4 expression in leiomyoma and myometrium: inverse association with TGF-{beta} and regulation by TGF-{beta} in leiomyoma and myometrial smooth muscle cells Mol. Hum. Reprod., April 1, 2006; 12(4): 245 - 256. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Levens, X. Luo, L. Ding, R. S. Williams, and N. Chegini Fibromodulin is expressed in leiomyoma and myometrium and regulated by gonadotropin-releasing hormone analogue therapy and TGF-{beta} through Smad and MAPK-mediated signalling Mol. Hum. Reprod., July 1, 2005; 11(7): 489 - 494. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Luo, L. Ding, J. Xu, R. S. Williams, and N. Chegini Leiomyoma and Myometrial Gene Expression Profiles and Their Responses to Gonadotropin-Releasing Hormone Analog Therapy Endocrinology, March 1, 2005; 146(3): 1074 - 1096. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Luo, L. Ding, J. Xu, and N. Chegini Gene Expression Profiling of Leiomyoma and Myometrial Smooth Muscle Cells in Response to Transforming Growth Factor-{beta} Endocrinology, March 1, 2005; 146(3): 1097 - 1118. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Ding, J. Xu, X. Luo, and N. Chegini Gonadotropin Releasing Hormone and Transforming Growth Factor {beta} Activate Mitogen-Activated Protein Kinase/Extracellularly Regulated Kinase and Differentially Regulate Fibronectin, Type I Collagen, and Plasminogen Activator Inhibitor-1 Expression in Leiomyoma and Myometrial Smooth Muscle Cells J. Clin. Endocrinol. Metab., November 1, 2004; 89(11): 5549 - 5557. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Luo, L. Ding, and N. Chegini Gonadotropin-releasing hormone and TGF-{beta} activate MAP kinase and differentially regulate fibronectin expression in endometrial epithelial and stromal cells Am J Physiol Endocrinol Metab, November 1, 2004; 287(5): E991 - E1001. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Shozu, K. Murakami, T. Segawa, T. Kasai, H. Ishikawa, K. Shinohara, M. Okada, and M. Inoue Decreased Expression of Early Growth Response-1 and Its Role in Uterine Leiomyoma Growth Cancer Res., July 1, 2004; 64(13): 4677 - 4684. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Maruo, N. Ohara, J. Wang, and H. Matsuo Sex steroidal regulation of uterine leiomyoma growth and apoptosis Hum. Reprod. Update, May 1, 2004; 10(3): 207 - 220. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Chegini, J. Verala, X. Luo, J. Xu, and R. S. Williams Gene Expression Profile of Leiomyoma and Myometrium and the Effect of Gonadotropin Releasing Hormone Analogue Therapy Reproductive Sciences, April 1, 2003; 10(3): 161 - 171. [Abstract] [PDF] |
||||
![]() |
J. Xu, X. Luo, and N. Chegini Differential Expression, Regulation, and Induction of Smads, Transforming Growth Factor-{beta} Signal Transduction Pathway in Leiomyoma, and Myometrial Smooth Muscle Cells and Alteration by Gonadotropin-Releasing Hormone Analog J. Clin. Endocrinol. Metab., March 1, 2003; 88(3): 1350 - 1361. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Chegini and L. Kornberg Gonadotropin Releasing Hormone Analogue Therapy Alters Signal Transduction Pathways Involving Mitogen-Activated Protein and Focal Adhesion Kinases in Leiomyoma Reproductive Sciences, January 1, 2003; 10(1): 21 - 26. [Abstract] [PDF] |
||||
![]() |
N. Chegini, C. Ma, X.M. Tang, and R.S. Williams Effects of GnRH analogues, `add-back' steroid therapy, antiestrogen and antiprogestins on leiomyoma and myometrial smooth muscle cell growth and transforming growth factor-{beta} expression Mol. Hum. Reprod., December 1, 2002; 8(12): 1071 - 1078. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Wu, A. Blanck, G. Norstedt, L. Sahlin, and A. Flores-Morales Identification of genes with higher expression in human uterine leiomyomas than in the corresponding myometrium Mol. Hum. Reprod., March 1, 2002; 8(3): 246 - 254. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Shozu, H. Sumitani, T. Segawa, H.-J. Yang, K. Murakami, and M. Inoue Inhibition of in Situ Expression of Aromatase P450 in Leiomyoma of the Uterus by Leuprorelin Acetate J. Clin. Endocrinol. Metab., November 1, 2001; 86(11): 5405 - 5411. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Chegini, K. Kotseos, Y. Zhao, B. Bennett, F. W. McLean, M. P. Diamond, L. Holmdahl, and J. Burns Differential expression of TGF-{beta}1 and TGF-{beta}3 in serosal tissues of human intraperitoneal organs and peritoneal adhesions Hum. Reprod., June 1, 2001; 16(6): 1291 - 1300. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. M. P. J. Reijnen, H. van Goor, P. Falk, M. Hedgren, and L. Holmdahl Sodium Hyaluronate Increases the Fibrinolytic Response of Human Peritoneal Mesothelial Cells Exposed to Tumor Necrosis Factor {alpha} Arch Surg, March 1, 2001; 136(3): 291 - 296. [Abstract] [Full Text] [PDF] |
||||
![]() |
B.-S. Lee and R. A. Nowak Human Leiomyoma Smooth Muscle Cells Show Increased Expression of Transforming Growth Factor-{beta}3 (TGF{beta}3) and Altered Responses to the Antiproliferative Effects of TGF{beta} J. Clin. Endocrinol. Metab., February 1, 2001; 86(2): 913 - 920. [Abstract] [Full Text] |
||||
![]() |
S. Hague, L. Zhang, M. K. Oehler, S. Manek, I. Z. MacKenzie, R. Bicknell, and M. C. P. Rees Expression of the Hypoxically Regulated Angiogenic Factor Adrenomedullin Correlates with Uterine Leiomyoma Vascular Density Clin. Cancer Res., July 1, 2000; 6(7): 2808 - 2814. [Abstract] [Full Text] |
||||
![]() |
C. Ma and N. Chegini Regulation of matrix metalloproteinases (MMPs) and their tissue inhibitors in human myometrial smooth muscle cells by TGF-{beta}1 Mol. Hum. Reprod., October 1, 1999; 5(10): 950 - 954. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Chegini, C. Ma, J. Davis, P. Duff, and C. Rosa Differential Expression of Transforming Growth Factor-{beta}1 and Transforming Growth Factor-{beta} Receptors in Myometrium of Women With Failed Induction of Labor, No Labor, and Preterm Labor Reproductive Sciences, September 1, 1999; 6(5): 258 - 263. [Abstract] [PDF] |
||||
![]() |
N. Chegini, X.-M. Tang, and Q. Dou The expression, activity and regulation of granulocyte macrophage-colony stimulating factor in human endometrial epithelial and stromal cells Mol. Hum. Reprod., May 1, 1999; 5(5): 459 - 466. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. K. Roy, S. G. Kurz, A. M. Carlson, C. J. DeJonge, J. W. Ramey, and V. M. Maclin Transforming Growth Factor ß Receptor Expression in Hyperstimulated Human Granulosa Cells and Cleavage Potential of the Zygotes Biol Reprod, December 1, 1998; 59(6): 1311 - 1316. [Abstract] [Full Text] |
||||
![]() |
E. Levens, X. Luo, L. Ding, R. S. Williams, and N. Chegini Fibromodulin is expressed in leiomyoma and myometrium and regulated by gonadotropin-releasing hormone analogue therapy and TGF-{beta} through Smad and MAPK-mediated signalling Mol. Hum. Reprod., July 1, 2005; 11(7): 489 - 494. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |